肝細胞癌に対するマイクロ波凝固療法とラジオ波凝固療法の成績の比較

概要

論文の詳細を見る
Twenty-five patients with solitary HCC were firstly treated by laparoscopic microwave coagulation (LMC), 14 were also treated by percutaneous microwave coagulation (PMC), 5 were also treated by laparoscopic radiofrequency ablation (LRFA), and 28 were also treated by percutaneous radiofrequency ablation (PRFA). For these 72 cases, we analyzed the survival rates and compared the rates among LMC, PMC, and PRFA group. Three-year survival rates were 91% in LMC group, 92% in PMC group, and 96% in PRFA group. The differences of survival rates were not statistically significant among LMC, PMC, and PRFA group. Next, we analyzed disease-free survival rates among LMC, PMC, and PRFA group. 3-year disease-free survival rates were 31% in LMC group, 22% in PMC group, and 41% in PRFA group. The differences of disease-free survival rates were not statistically significant among LMC, PMC, and PRFA group. The therapeutic efficacy is thought to be equal between microwave coagulation and radiofrequency ablation.